LINC00460 and urinary bladder carcinoma: LINC00460 has been reported in various tumors such as head and neck squamous cell carcinoma (Yang et al., 2021b), cervical cancer (Lin et al., 2020), bladder cancer (Li et al., 2021), colorectal cancer (Ruan et al., 2021), and is implicated in tumor proliferation, migration, mesenchymal transition, drug resistance, and increased tumor progression (Meng et al., 2020; Cheng et al., 2021).